ATE424217T1 - Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen - Google Patents

Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Info

Publication number
ATE424217T1
ATE424217T1 AT98963052T AT98963052T ATE424217T1 AT E424217 T1 ATE424217 T1 AT E424217T1 AT 98963052 T AT98963052 T AT 98963052T AT 98963052 T AT98963052 T AT 98963052T AT E424217 T1 ATE424217 T1 AT E424217T1
Authority
AT
Austria
Prior art keywords
chemokines
compositions
vaccines
efficiency
increase
Prior art date
Application number
AT98963052T
Other languages
English (en)
Inventor
Robert Gallo
Anthony Devico
Alfredo Garzino-Demo
Original Assignee
Univ Maryland Biotech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst
Application granted granted Critical
Publication of ATE424217T1 publication Critical patent/ATE424217T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT98963052T 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen ATE424217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6928197P 1997-12-11 1997-12-11

Publications (1)

Publication Number Publication Date
ATE424217T1 true ATE424217T1 (de) 2009-03-15

Family

ID=22087917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963052T ATE424217T1 (de) 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Country Status (6)

Country Link
EP (1) EP1037918B1 (de)
AT (1) ATE424217T1 (de)
AU (1) AU1815899A (de)
CA (1) CA2314006A1 (de)
DE (1) DE69840637D1 (de)
WO (1) WO1999029728A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
CA2326685C (en) * 1998-04-22 2013-08-06 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US7708983B2 (en) 1998-12-11 2010-05-04 Alfredo Garzino-Demo Directional induction of immune response by co-administration of antigens with chemokines
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response
EP1274454B1 (de) * 2000-04-21 2005-12-28 Chemocentryx, Inc. Methoden und zusammensetzungen zur induzierung einer immunantwort
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
AU2002228729A1 (en) * 2001-04-12 2002-11-05 Chemocentryx Methods and compositions for inducing an immune response to an antigen
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
SK16497A3 (en) * 1995-06-07 1998-05-06 Icos Corp Macrophage derived chemokine and chemokine analogs

Also Published As

Publication number Publication date
EP1037918A4 (de) 2004-11-03
CA2314006A1 (en) 1999-06-17
WO1999029728A1 (en) 1999-06-17
EP1037918A1 (de) 2000-09-27
DE69840637D1 (de) 2009-04-16
EP1037918B1 (de) 2009-03-04
AU1815899A (en) 1999-06-28

Similar Documents

Publication Publication Date Title
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
ATE446363T1 (de) Antisense-modulation der survivin-expression
ATE496127T1 (de) Antisense-modulation der clusterinexpression
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
SE9801455D0 (sv) New receptor
DE68911132D1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
SE9602822D0 (sv) New receptor
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
EA199800819A1 (ru) Способ лечения биполярного расстройства
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ATE247649T1 (de) Disubstituierte biphenyloxazoline
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
DE60207574D1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
NO982151L (no) Hemoregulatoriske forbindelser
ITFE930013U1 (it) Bacchette orientali meccanizzate.
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ITPD960101U1 (it) Aceto di miele balsamico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties